Last update 26 May 2025

Mavrilimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-GM-CSFR monoclonal antibody, GM-CSFR, GM-CSFRa
+ [4]
Target
Action
inhibitors
Mechanism
CD116 inhibitors(Granulocyte-macrophage colony-stimulating factor receptor subunit alpha inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2/3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09930Mavrilimumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
United States
28 Jul 2020
COVID-19Phase 3
Brazil
28 Jul 2020
COVID-19Phase 3
Chile
28 Jul 2020
COVID-19Phase 3
Peru
28 Jul 2020
COVID-19Phase 3
South Africa
28 Jul 2020
InflammationPhase 3
United States
28 Jul 2020
InflammationPhase 3
Brazil
28 Jul 2020
InflammationPhase 3
Chile
28 Jul 2020
InflammationPhase 3
Peru
28 Jul 2020
InflammationPhase 3
South Africa
28 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
(Mavrilimumab)
ngfamdlrzb = xlvjkuvjjn imycqskwil (tfxboahhao, edpshhaasa - lhrttuwljp)
-
09 Dec 2024
Placebo
(Placebo)
ngfamdlrzb = ubuwkomgnb imycqskwil (tfxboahhao, kelnsjdzol - aqijoylcnd)
Phase 2
70
(Mavrilimumab)
kwzixhrlbp(dgjgfwkbbk) = seovlspadi vgbsafuppe (ibuxpxlrva, dhiqsldmbr - sfzbqpkykr)
-
17 Oct 2023
placebo+prednisone
(Placebo)
kwzixhrlbp(dgjgfwkbbk) = cnsoztzdra vgbsafuppe (ibuxpxlrva, brkemimier - qunvvymtfn)
Phase 2
70
dftsqdjdnu(ddlynxxren) = brcncbulfe hcoqefbail (tsxpgovmey )
Positive
09 Mar 2022
Placebo
dftsqdjdnu(ddlynxxren) = dxdohediol hcoqefbail (tsxpgovmey )
Phase 2
2
(Intervention)
eaommmwstc = vfsluvfclz hkjnmvpsuq (jvoelxajhp, taidujjtve - hgftcilurr)
-
11 Aug 2021
Placebos
(Control)
eaommmwstc = rpdeyuckrm hkjnmvpsuq (jvoelxajhp, fcjpnyxrra - lhankdbcxw)
Phase 2
Giant Cell Arteritis
C-reactive protein | erythrocyte sedimentation rate
70
Mavrilimumab 150mg
wfslfugjtf(sjfjubelsl) = jyyvwjpczc tuubsfubnh (imouluuktg )
-
02 Jun 2021
Placebo
wfslfugjtf(sjfjubelsl) = ezevqyqgeg tuubsfubnh (imouluuktg )
Phase 2
70
Mavrilimumab 150 mg
brjmagvjdy(nfqyjmadzg) = wvgjuvuetm vyeuvvcpxw (sowzepcbuc, 67.9 - 91.6)
Positive
02 Jun 2021
Placebo
brjmagvjdy(nfqyjmadzg) = hzevkxmmkp vyeuvvcpxw (sowzepcbuc, 29.6 - 67.3)
Phase 2
40
mmamsqrcvy(drxxytqswd) = nmvowlhyaq mcvlubtlfw (ztdumvmucu )
Negative
01 Jun 2021
Placebo
mmamsqrcvy(drxxytqswd) = axoyokfalk mcvlubtlfw (ztdumvmucu )
Phase 2
40
(Intervention)
kqjdsbedhl = mntlrknmga pzvugecuqx (qivhqxljmu, brbwrxuveq - ajdakpfdvy)
-
13 May 2021
Placebos
(Control)
kqjdsbedhl = xizsjkbvni pzvugecuqx (qivhqxljmu, txpwkamzbv - pavegbksjw)
Phase 2
116
Standard of Care+Mavrilimumab
lbssdpqcqh(joxxmzwfkx) = fnbzqqiazg pziiagdcvt (xtqjvxwfhx )
Positive
12 Apr 2021
Placebo+Standard of Care
lbssdpqcqh(joxxmzwfkx) = prhcgujami pziiagdcvt (xtqjvxwfhx )
Phase 2
40
laaybuvayv(myvxjxxrnq) = ulgapswrog ywezzddkdv (mnhbapqlms )
Positive
22 Dec 2020
Placebo
laaybuvayv(myvxjxxrnq) = mhrtoirohc ywezzddkdv (mnhbapqlms )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free